Collegium Pharmaceutical (NasdaqGS:COLL) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Speaker5Greetings! Welcome to the Collegium Pharmaceutical fourth quarter and full year 2025 earnings conference call. At this time, all participants are in listen-only mode. A question-and-answer session will follow the formal presentation. If anyone should require operator assistance during this conference call, please press star zero on your telephone keypad. Please note, this conference call is being recorded. I ...

ACADIA Pharmaceuticals (NasdaqGS:ACAD) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Company ParticipantsAl Kildani - Senior Vice President of Investor Relations and Corporate CommunicationsAsh Verma - DirectorCaroline Palavicino-Maggio - VPCatherine Owen Adams - CEODavid Hoang - DirectorElizabeth Thompson - EVP and Head of Research and DevelopmentJason Butler - Managing DirectorJulian Pino - AssociateMarc Goodman - Senior Managing Director in NeuroscienceMark Breidenbach - DirectorMark Schneyer - CFO ...

Summary of Enovis Conference Call Company Overview - **Company**: Enovis - **Industry**: Orthopedics - **Revenue**: Approximately $2 billion with a growth rate of around 6% [4][5] - **Focus**: Mobility and the continuum of care, with a balanced portfolio in orthopedic implants and prevention/recovery [4][5] Key Points Growth and Financial Performance - Enovis raised guidance on EBITDA and EPS, indicating positive financial momentum [5] - The company is experiencing growth driven by a mix of acquisitions and organic growth, with a core growth rate of about 6% excluding M&A [7] - Gross margins improved from approximately 14% to 18%, with a pathway to reach 20% [7] - The prevention and recovery (P&R) business has shifted from low single-digit growth to mid-single-digit growth [8] Strategic Focus - Enovis is concentrating on commercial execution, innovation, and financial discipline post-acquisitions [6] - The company aims to embed a "One Enovis" mindset to enhance collaboration and operational efficiency [9] - Continuous improvement and lean methodologies are being implemented across the organization [10] Product Portfolio and Innovation - Enovis has launched several new products, including the EMPOWR knee and ManiFuse, which are expected to drive future growth [11][29] - The company is leveraging its acquisitions to enhance product offerings and market reach, particularly in the shoulder and extremities segments [28][29] - The introduction of the ARVIS 2.0 robotic system is anticipated to support implant sales, although it will not be a standalone revenue line [34][36] Market Position and Competitive Advantage - Enovis has established a strong market presence, with significant brand loyalty in the P&R segment, particularly with the DonJoy brand [5][13] - The company is positioned to capitalize on trends in mobility health, including gut health, brain health, and overall mobility [10] Financial Goals and Cash Flow - Enovis aims for a free cash flow conversion of over 25% in 2026, with a long-term goal of 70% [16][51] - The company is focused on reducing integration costs and improving working capital efficiency to enhance cash flow generation [51][52] - Adjusted EBITDA and EPS are expected to improve, driven by a favorable product mix and cost management [25][26] Challenges and Considerations - The company experienced a slight softness in sales towards the end of the year, attributed to timing issues with ordering patterns [22] - Tariff impacts are expected to be slightly negative in 2026, but Enovis is confident in its ability to mitigate these effects [48][50] Future Outlook - Enovis is targeting mid-single-digit organic growth for 2026, with potential for higher growth driven by improved commercial execution and product introductions [20][30] - The company is committed to maintaining a disciplined approach to capital allocation and margin expansion as it continues to integrate acquisitions [41][45] Additional Insights - The integration of the LimaCorporate acquisition is progressing well, with expectations to achieve $40 million in cost synergies [40] - Enovis is focusing on organic R&D capabilities, moving away from reliance on acquisitions for innovation [42][44] - The company is actively working on improving its sales organization and targeting strategies to enhance market penetration [31][32]

Financial Data and Key Metrics Changes - Worldwide revenue reached $48.7 million in Q3 2025, representing approximately 21% growth year-over-year [4][17] - U.S. revenue grew over 21% to $46.4 million, driven by increased adoption of solutions [4][17] - Positive adjusted EBITDA of $2.3 million for the quarter, translating to an adjusted EBITDA margin of approximately 5% [5][19] - Gross profit was $38.8 million, an increase of $6.9 million or 21.8%, with a gross margin of 79.8% [17][18] - Net loss narrowed to $4.6 million, or $0.11 per diluted share, compared to a net loss of $6.6 million, or $0.16 per diluted share [18][19] Business Line Data and Key Metrics Changes - The flagship solutions continue to perform well in a large, under-penetrated market, with double-digit volume growth across all modalities [5][6] - The interventional case volume doubled compared to Q3 2024, indicating strong adoption of clinically validated solutions [7] - The number of procedures using more than two Granite implants per case grew approximately 40% in the quarter [9] Market Data and Key Metrics Changes - International revenue in Q3 was $2.3 million, representing 10.2% growth, with expectations for acceleration in 2026 due to the launch of iFuse TORQUE [17][18] - The company added 330 physicians in the quarter, marking a 27% year-over-year increase in active physicians [12][48] Company Strategy and Development Direction - The company aims to expand its addressable market by adding new applications of technology and expertise, focusing on compromised bone [22][23] - Plans to launch several innovative solutions over the next five years to address poor bone quality [12][54] - The company is focused on operational excellence, with a disciplined pricing strategy and ongoing supply chain optimization initiatives [18][19] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining strong top-line growth, expanding margins, and achieving positive free cash flow in 2026 [22][34] - The company anticipates continued physician engagement and adoption trends, with a significant opportunity to increase procedure density [12][15] - Management highlighted the importance of favorable reimbursement changes and the potential for new product launches to drive growth [37][61] Other Important Information - The company achieved its second consecutive quarter of net cash flow breakeven, ending the quarter with $145.7 million in cash and marketable securities [20][21] - The company is actively pursuing regulatory clearance to commercialize additional products across several international markets [17][56] Q&A Session Summary Question: Discussion on physician density and operating leverage - Management emphasized the importance of physician density and the opportunity to grow by increasing the use of technology across different procedure types [24][25] - Operating leverage is expected to range between 1.25-1.75 times, with a focus on delivering strong top-line growth [27][28] Question: Guidance update and momentum in Q4 - Management raised the full-year revenue guidance to $198 million-$200 million, reflecting continued outperformance and strong momentum heading into Q4 [30][32] Question: Trends in cash burn expectations - Management expects to use some cash in Q4 for building surgical capacity but remains confident in achieving free cash flow in 2026 [34] Question: Insights on TNT and NTAP adoption - Management expressed excitement about the NTAP, which represents a significant reimbursement improvement, and noted strong interest from national distributors for TNT [57][59] Question: Long-term profitability and operating leverage - Management highlighted the unique business model that allows for high ASP and operating leverage, with expectations for margin expansion as new products contribute to revenue [61][62]

Financial Data and Key Metrics Changes - The company reported a 5% increase in sales on an organic, constant currency basis for Q3 2025, with adjusted earnings per share (EPS) of $1.90, up 9.2% year over year [5][20][24] - U.S. business sales grew 5.6% on an organic basis, marking the best revenue growth performance since mid-2023 [5][21] - Adjusted gross margin improved to 72.6%, while adjusted operating margin was 26.5%, reflecting better gross margin and lower manufacturing costs [24] Business Line Data and Key Metrics Changes - The U.S. knee segment saw a growth of 3.5%, driven by the adoption of Persona Osteotide and Oxford partial cementless knee products [6][22] - The robotics and navigation segment increased by 20.3%, with ROSA accounts performing over half of their knee implants robotically [8][21] - The upper extremities business grew in the high single digits, while cranial, maxillofacial, and thoracic (CMFT) business increased over 20% due to new product introductions [10][21] Market Data and Key Metrics Changes - International revenue grew by 4.2%, with emerging markets presenting a headwind to growth [21][22] - The global needs segment grew 5.3%, with U.S. needs increasing by 3.5% and international needs by 7.8% [22] - The company experienced unexpected weakness in Eastern Europe, Latin America, and non-core segments, impacting growth by nearly 120 basis points [6][20] Company Strategy and Development Direction - The company focuses on three strategic priorities: people and culture, operational excellence, and innovation and diversification [11][12] - Recent acquisitions, including Monogram Technologies, aim to enhance the company's robotics capabilities and expand its product offerings [15][17] - The company is committed to maintaining a disciplined approach to capital allocation while pursuing growth opportunities in high-growth markets [40] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in addressing identified issues and remains optimistic about the market reception of new products [6][19] - The updated guidance for 2025 reflects a more measured outlook due to continued weakness in restorative therapies and challenges in certain international markets [10][26] - Management emphasized the importance of innovation and commercial execution in driving future growth [19][59] Other Important Information - The company updated its full-year organic constant currency revenue growth expectations to a range of 3.5% to 4% [10][26] - Free cash flow for the year is projected to be between $1 billion and $1.2 billion, with operating cash flows of $419 million reported for the quarter [25][26] Q&A Session Summary Question: Guidance philosophy and Q3 performance - Management acknowledged unexpected cancellations and challenges in emerging markets that impacted growth, emphasizing a need for more measured external commentary moving forward [30][34] Question: Future headwinds and capital allocation - Management indicated that the recent challenges are not expected to impact 2025 guidance and highlighted a disciplined approach to capital allocation, focusing on growth markets [38][40] Question: Performance against long-range plan (LRP) targets - Management noted that while current growth is mid-single digits, future acceleration will depend on market dynamics, innovation, and commercial execution [42][44] Question: Product pipeline and innovation - Management discussed the successful rollout of new products and the potential for significant revenue contributions from breakthrough technologies in the coming years [46][55] Question: U.S. knee market share - Management acknowledged potential market share loss but emphasized improved growth rates and the positive impact of new product introductions [60]

Financial Data and Key Metrics Changes - The company reported total revenue of $69.5 million for Q3 2025, including record net product sales of $64.1 million, a 65% year-over-year increase [4][27] - Net income for the third quarter was $27.9 million, compared to $12.4 million for the same period in 2024 [29] - Cash balance increased to $137.1 million, up from $77.3 million at the end of 2024 [29] Business Line Data and Key Metrics Changes - TAVALISSE generated $44.7 million in net product sales, a 70% increase year-over-year [11][27] - GAVRETO achieved $11.1 million in net product sales, reflecting a 56% increase compared to Q3 2024 [12][27] - REZLIDHIA reported $8.3 million in net product sales, a 50% increase year-over-year [12][27] Market Data and Key Metrics Changes - The company has expanded access to TAVALISSE in Japan, Europe, Canada, Israel, and South Korea, with ongoing regulatory approvals in new markets [13] - The commercial portfolio has shown strong year-over-year growth, with net product sales exceeding $200 million on a trailing 12-month basis [11] Company Strategy and Development Direction - The strategic objectives focus on growing the hematology and oncology business through commercial performance and pipeline expansion [4] - The company is pursuing additional in-licensing deals or asset acquisitions to achieve significant growth [7] - The 2025 revenue guidance has been raised to $285-$290 million, reflecting anticipated growth of 55%-59% compared to 2024 [9][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to achieve significant long-term growth through strong commercial execution and financial discipline [9][32] - The company aims to continue driving sales of commercial products while funding key development programs in its internal pipeline [31][32] Other Important Information - The company is advancing its development pipeline, including the ongoing phase 1b study of R289 and collaborations for olutasidenib in various cancer studies [5][16] - The company has received fast-track designation and orphan drug designation from the FDA for R289, indicating a promising regulatory pathway [19] Q&A Session Summary Question: Competitive positioning of R289 in lower-risk MDS versus Rytelo - Management indicated it is too early to speculate on competitive positioning and plans for a registrational study [34] Question: Data needed for potential priority review of R289 - Management noted that the fast-track designation opens potential for priority review, but further data from the dose expansion study is needed [38] Question: Expectations for updated data at ASH for R289 - Management confirmed that updated data will include 16 weeks of follow-up on all patients, providing a robust data set for presentation [40]

Financial Performance - AbbVie reported adjusted earnings per share of $1.86, exceeding guidance by $0.10 [4][28] - Total net revenues reached nearly $15.8 billion, reflecting an operational growth of 8.4% [28] - Adjusted gross margin was 83.9% of sales, with adjusted R&D expense at 14.3% and adjusted SG&A expense at 21.6% [28] Business Line Performance - Immunology revenues totaled approximately $7.9 billion, up 11.2% operationally, driven by SKYRIZI and RINVOQ, which saw sales growth of 46% and 34.1% respectively [10][11] - Oncology revenues were nearly $1.7 billion, remaining flat year-over-year, with VENCLEXTA and newer products offsetting declines from IMBRUVICA [13][14] - Neuroscience revenues exceeded $2.8 billion, up 19.6%, with strong performances from Ubrelvy, Qulipta, and Vraylar [17][18] - Aesthetics sales were approximately $1.2 billion, down 4.2%, impacted by challenging market conditions [14][15] Market Dynamics - SKYRIZI and RINVOQ are gaining significant market share in gastroenterology, capturing nearly 50% of newer switching Crohn's patients in the U.S. [10][11] - Humira's global sales declined by 55.7% to $993 million due to biosimilar competition [13] - The aesthetics market is facing low consumer sentiment and inflation concerns, leading to below-expected category growth [16] Strategic Direction - AbbVie is raising its 2025 outlook for the third time this year, indicating strong business performance and pipeline advancement [4][5] - The company plans to invest at least $10 billion in the U.S. over the next decade, with ongoing construction of new manufacturing sites [8] - AbbVie is focusing on expanding its pipeline with approximately 90 programs across various therapeutic areas, including immunology, oncology, and neuroscience [5][6] Management Commentary - Management expressed confidence in the company's ability to adapt to changes in the PBM model and emphasized the importance of differentiated medicines for growth [35][36] - The management highlighted the strong performance of SKYRIZI and RINVOQ, with expectations for continued growth despite challenges from Humira erosion [46][52] Other Important Information - AbbVie announced a 5.5% increase in its quarterly cash dividend, reflecting a commitment to delivering sustainable returns to shareholders [8][31] - The company has executed approximately 30 deals since the beginning of 2024, focusing on external innovation to drive growth [32] Q&A Session Summary Question: Implications of new PBM model and IRA price negotiations - Management indicated that AbbVie's performance is driven by differentiated medicines and strong execution, allowing adaptability to changes in the PBM model [35][36] - The outcomes of IRA price negotiations for Vraylar and Linzess will not impact long-term guidance [38] Question: Competitive dynamics in the IL-23 market - Management expressed confidence in SKYRIZI's growth and its leadership position in IBD, despite competition from Tremfya [42][44] - The IL-23 class is expanding rapidly, benefiting all players in the market [42] Question: 2026 outlook and business dynamics - Management noted strong performance across the neuroscience portfolio and anticipates continued growth despite headwinds from Humira erosion [46][47] Question: Long-term guidance for SKYRIZI and RINVOQ - Management indicated that the combined guidance for SKYRIZI and RINVOQ for 2025 has been raised significantly, suggesting potential for exceeding long-term expectations [51][52] Question: Market conditions for aesthetics products - Management acknowledged challenges in the U.S. aesthetics market but emphasized ongoing investments to revitalize the segment [56][57]

Financial Data and Key Metrics Changes - The company reported record-setting third quarter net sales and earnings results, achieving a year-over-year top-line growth of 10% [4][5] - Consolidated adjusted EBITDA increased by 6%, while adjusted net earnings per share rose by 13% [5][20] - Free cash flow grew significantly, with a double-digit increase both in the quarter and year-to-date [5][20] Business Line Data and Key Metrics Changes - In the Mineral Fiber segment, net sales increased by 6% year-over-year, driven by strong average unit value (AUV) growth and positive sales volume contributions [8][17] - The Architectural Specialties segment saw a net sales increase of 18%, supported by acquisitions and solid organic growth [12][19] Market Data and Key Metrics Changes - The company noted stabilizing market conditions, with no anticipated softening in discretionary renovation activity, contrary to earlier expectations [28][90] - The office market showed signs of improvement, with declining vacancy rates for Class A offices and increased demand for renovations in Class B spaces [30][31] Company Strategy and Development Direction - The company remains focused on operational efficiency, commercial execution, and growth initiatives to navigate a dynamic macroeconomic environment [7][8] - Investments in digital growth initiatives like PROJECTWORKS and Kanopi are expected to drive volume and contribute to margin expansion [15][16] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving strong results for the remainder of 2025, with expectations for continued double-digit growth in net sales and adjusted EBITDA [27][35] - The company anticipates a full-year adjusted EBITDA margin of approximately 43% for the Mineral Fiber segment, the highest since 2019 [10][25] Other Important Information - The company announced a 10% increase in its quarterly dividend, marking the seventh consecutive annual increase since the inception of its dividend program [24] - The acquisition of Geometrik, a Canadian wood ceiling manufacturer, was completed for $7.5 million, enhancing the company's product offerings and geographic diversification [14][23] Q&A Session Summary Question: Can you talk about the benefit that you're seeing from the new products? - Management noted that innovation at the high end of the portfolio is driving double-digit growth in both the Mineral Fiber and Architectural Specialties segments [39][40] Question: What is the outlook for Architectural Specialties margins? - Management expects to maintain organic margins around 20% while continuing to focus on growth opportunities [43][44] Question: Can you elaborate on the timing-related cost headwinds? - Management highlighted that higher SG&A costs were driven by increased incentive compensation and atypical medical claims, which are not expected to persist [50][51] Question: What is the outlook for the education and healthcare segments? - Management indicated that both segments remain stabilized, with positive trends in healthcare and robust opportunities in data centers [54][55] Question: How do you view the potential for Mineral Fiber margins to exceed pre-pandemic levels? - Management emphasized that continued focus on pricing, productivity, and innovation will support margin expansion beyond pre-pandemic levels [92][93]

Core Insights - The company has experienced strong demand for its products, which aligns with initial expectations [1] - The company holds a leadership position in attractive markets, supported by strong brand equity and effective commercial execution [2]

Financial Data and Key Metrics Changes - Worldwide revenue for Q1 2025 reached $47.3 million, representing approximately 25% growth compared to the prior year [6][26] - U.S. revenue was $44.8 million, reflecting approximately 27% growth, driven by a 27.3% increase in procedure volume [7][26] - Gross profit was $37.7 million, an increase of $7.8 million or 26.2%, with a gross margin rate of 79.7% [27] - Net loss narrowed to $6.5 million or $0.15 per diluted share, compared to a net loss of $10.9 million or $0.27 per diluted share in the prior year [28] - Positive adjusted EBITDA of approximately $5 million compared to an adjusted EBITDA loss of $4 million in Q1 2024 [29] Business Line Data and Key Metrics Changes - The company experienced broad-based demand for existing technologies and rapid adoption of new solutions launched in 2024 [7][39] - The number of physicians performing procedures using the company's products grew by 27%, with over 1,400 U.S. physicians engaged [19] - The number of four implant Granite cases grew approximately 69% compared to the prior year period [13] Market Data and Key Metrics Changes - The total addressable market has increased to over $3.5 billion, with a cumulative procedure volume growth of 25% over the last three years [9][10] - The company is targeting nearly 100,000 degenerative procedures annually with its Granite product, which became eligible for transitional pass-through payment starting January 1, 2025 [13][14] Company Strategy and Development Direction - The company focuses on innovation, engagement, commercial execution, and operational excellence as key priorities [9] - The strategy includes diversifying the product platform with unique yet complementary technologies to expand the target modalities and physician footprint [9][10] - The company aims to reach 100 territories over the next 12 to 15 months, leveraging a hybrid commercial model combining territory managers and third-party agents [24][58] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver strong results over the long term, supported by resilient business trends and favorable reimbursement conditions [8][9] - The updated full-year revenue guidance is between $193.5 million to $197.5 million, implying year-over-year growth of approximately 16% to 18% [32] - Management noted that the company is well-positioned to achieve free cash flow in 2026, with a focus on maintaining operational discipline [30][32] Other Important Information - The company has a strong pipeline of novel technologies under development, with plans to launch new products over the next 12 to 18 months [16][18] - The company does not anticipate any material impact on gross margins or supply chain from proposed tariffs, as most manufacturing is domestic [30][31] Q&A Session Summary Question: Contribution from new products and channels to growth - Management noted broad-based growth and strong demand for current solutions, with impressive adoption of new products launched in 2024 [39] Question: Drivers of gross margin and future expectations - Management highlighted better-than-expected average selling price (ASP) and efficiency initiatives as key drivers of gross margin improvement [42][44] Question: Long-term growth expectations - Management expressed confidence in sustained growth potential, driven by technology leadership and expanding physician engagement [53][56] Question: Expected cadence of new guidance and sequential growth - Management indicated that while they do not think about the business in quarters, they expect to manage seasonality effectively with new product rollouts [66] Question: Operating expenses guidance - Management explained that elevated R&D investments and higher commissions linked to revenue growth are driving the expected increase in operating expenses [70][72] Question: Update on surgeon base and engagement - Management reported a record increase in the physician base, with broad engagement across various specialties [76][78] Question: Updates on reimbursement proposals - Management provided insights on CMS proposals and the potential for increased reimbursement rates, which could accelerate adoption of products [80][81] Question: Traction and adoption of TNT product - Management noted that TNT is seeing rapid adoption and is expected to benefit from upcoming reimbursement changes [97]